Wednesday, November 9, 2011
Celldex Therapeutics Inc., of Needham, Mass., initiated a Phase I study of CDX-1127 in patients with selected malignant solid tumors or hematologic cancers. A human monoclonal antibody that binds CD27, a co-stimulatory molecule on T cells, CDX-1127 is designed to activate patients' immune cells against their cancer. The Phase I study will test five escalating doses of CDX-1127 to determine dosing for future trials. The multisite, U.S. study will enroll about 30 patients in each of two arms solid tumors or lymphomas/leukemias.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.